跳到正文
原文
STAT 主站· Ed Silverman·· 2026-10-07AI 评分51

荷兰法院裁定默沙东 Keytruda 皮下制剂侵犯 Halozyme 专利,责令其在欧洲多国停售

STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

AI 导读

荷兰法院裁定默沙东的 Keytruda 皮下制剂侵犯 Halozyme 专利,责令该公司停止在法国、意大利、瑞典、瑞士和荷兰等欧洲国家制造和销售该制剂。现有的静脉注射版本不受影响,需要 Keytruda 的患者仍可继续使用。

正文

By Ed Silverman

Oct. 7, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

In a setback for Merck, a Dutch court ruled that the company infringed on a patent pertaining to a subcutaneous formulation of its Keytruda cancer treatment and was ordered to halt manufacturing and marketing the medication in several European countries, including France, Italy, Sweden, Switzerland, and the Netherlands.

The ruling came as part of a widening patent infringement dispute with Halozyme Therapeutics over the best-selling cancer treatment. Patients requiring Keytruda will still have access to the existing intravenous version, which is not affected by the patent dispute or court order.

We asked Merck for comment and will update you accordingly.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com